Univariate* | Multivariate† | Reduced multivariate‡ | Multivariate adjusting for clinical variables¶ | ||||||
Variable | Range | HR | P | HR | P | HR | P | HR | P |
Baseline sum of SUVmax | 0–181 | 1.03 (1.01, 1.04) | <0.001 | 1.03 (0.99, 1.06) | 0.084 | 1.01 (1.002, 1.03) | 0.024 | 1.02 (1.01, 1.03) | 0.004 |
Baseline maximum SUVmax | 0–21.9 | 1.11 (1.05, 1.17) | 0.002 | 1.12 (0.93, 1.33) | 0.26 | ||||
Baseline average SUVmax | 0–18.1 | 1.15 (1.04, 1.26) | 0.012 | 0.77 (0.51, 1.16) | 0.21 | ||||
Baseline disease sites (n) | 0–101 | 1.23 (1.13, 1.33) | <0.001 | 1.14 (1.02, 1.27) | 0.017 | 1.18 (1.08, 1.29) | <0.001 | 1.16 (1.03, 1.29) | 0.011 |
↵* Analysis of association between PET variables and THTF.
↵† Includes all 4 PET variables as independent variables.
↵‡ Includes only PET variables that are associated with THTF at P ≤ 0.05 after controlling for each other.
↵¶ Reports association between SUVmax or number of baseline disease sites with THTF after adjusting for clinical variables including age, baseline Gleason score, prostate-specific antigen level, and alkaline phosphatase level.
HR = hazard ratio.
Data in parentheses are 95% CIs.